ReviewAbdominal radiology (New York)2026
LI-RADS TRA V2024: innovations in imaging assessment of hepatocellular carcinoma response to locoregional therapies.
Review in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Liver Imaging Reporting and Data System (LI-RADS) has become an essential tool for standardizing the detection, diagnosis, and treatment response assessment of hepatocellular carcinoma (HCC) using contrast-enhanced CT and MRI. With the rising incidence of HCC, the use of local-regional therapies (LRT) has also expanded. To address the increasing complexity of post-treatment imaging interpretation, the LI-RADS Treatment Response Assessment (TRA) algorithm was developed to provide a structured and reproducible approach for evaluating tumor response following various forms of LRT. However, imaging features following radiation-based therapies-such as transarterial radioembolization and stereotactic body radiation therapy-often differ from those seen after thermal ablation and transarterial chemoembolization. Recognizing these differences, the 2024 LI-RADS TRA update introduces refinements to improve diagnostic accuracy in this context. This review outlines the evolving role of LI-RADS in post-treatment assessment, highlights imaging findings associated with different LRTs, and explores ongoing refinements aimed at optimizing its clinical utility. Finally, we discuss the need for prospective validation of the new algorithm to confirm its diagnostic performance and clinical impact.
Indexed as
Identifiers
40864274What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.